The European Medicines Agency has issued a report summarising actions that it has taken over the past four years to improve the availability of medicines for children. This activity is regulated by a Paediatric Regulation which came into force in the EU on 26 January 2007. The regulation establishes a special committee to coordinate the agency’s work in this area. The committee in turn decides which studies companies must carry out on children, alongside studies for the same disease that are being investigated in the adult population.
